Octapharma AG - Company Profile
Powered by 
All the sales intelligence you need on Octapharma AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Octapharma AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Octapharma AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Octapharma AG (Octapharma) develops and manufactures human protein medicines. The company produces medicines derived from human plasma and human cell lines. Octapharma's major products focus on three therapeutic areas: haematology, immunotherapy, and critical care. It provides products for individuals with bleeding disorders, supports immune system functions, and helps restore haemostasis and blood volume in critically ill patients. The company sources plasma from company-owned plasma donation centers and other external sources. Octapharma owns plasma donation centers in the US and Germany and owns production facilities in Austria, Germany, France, Mexico, and Sweden. Its production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labelling, packaging, storage, and distribution. Octapharma is headquartered in Lachen, Switzerland.
Headquarters
Switzerland
Address
Seidenstrasse 2, Lachen, Schwyz, 8853
Website
www.octapharma.com
Telephone
41 55 4512121
No of Employees
11,141
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$3.7B
Octapharma AG premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Human Protein | Plasma-Based Services | Albuminativ |
| Hematology | Albunorm | |
| Critical Care | Atenativ | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company was chosen as the sole fractionator by NHS England for the UK’s plasma-for-medicines programme, following the UK government-led procurement process after the ban on UK plasma was lifted. |
| 2025 | Corporate Changes/Expansions | In February, the company opened the expanded facilities at its manufacturing site in Vienna. |
| 2024 | Regulatory Approval | In April, the company was granted Orphan Drug exclusivity by the US FDA for wilate. |
Competitor Comparison
| Key Parameters | Octapharma AG | Abeona Therapeutics Inc | China Biologic Products Holdings Inc | Grifols USA LLC | Liminal BioSciences Inc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | China | United States of America | Canada |
| City | Lachen | Cleveland | Beijing | Los Angeles | Laval |
| State/Province | Schwyz | Ohio | Beijing | California | Quebec |
| No. of Employees | 11,141 | 136 | - | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wolfgang Marguerre | Chairman; Chief Executive Officer | Executive Board | - | - |
| Tobias Marguerre | Vice Chairman | Executive Board | - | - |
| Roger Machler | Chief Financial Officer | Senior Management | - | - |
| Josef Weinberger | Corporate Quality and Compliance Officer | Senior Management | - | - |
| Wolfgang Frenzel | Head - Research and Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer